Interview: An EU Plan To Pair Pharma With Life Science VCs
Making use of agencies' vast partner networks
Jan-Philipp Beck, CEO of EIT Health, believes a link-up with the European Investment Fund can only benefit the continent's biotech ecosystem.
You may also be interested in...
Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
The Mallorca-based biotech is building a strong data package for SNF472 which the company believes will be an effective treatment for a number of calcification disorders in dialysis patients.